导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -19.47% | 4339/4773 |
| 近一周 | -3.47% | 4211/5462 |
| 近一月 | -10.45% | 5084/5421 |
| 近一季 | -21.61% | 5069/5209 |
| 近半年 | -21.24% | 4441/4920 |
| 近一年 | -10.92% | 3460/4366 |
| 近两年 | 59.92% | 1213/2954 |
| 近三年 | 14.36% | 1651/2253 |
| 成立以来 | 133.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.04% 2078/4961 |
0.59% 3160/5312 |
- - |
- - |
| 2025 | 53.24% 392/4813 |
6.41% 639/3635 |
-0.88% 3052/4076 |
47.23% 472/4524 |
-1.32% 2897/4813 |
| 2024 | 0.81% 2050/3463 |
-6.90% 2094/2808 |
-9.58% 2376/3014 |
21.69% 554/3129 |
-1.60% 1764/3463 |
| 2023 | -26.22% 1985/2656 |
-1.95% 1907/2280 |
-5.27% 1413/2385 |
-14.86% 2199/2515 |
-6.70% 1881/2655 |
| 2022 | -26.92% 1441/2207 |
-16.08% 1098/1919 |
19.40% 89/2016 |
-22.86% 1941/2113 |
-5.46% 1931/2208 |
| 2021 | 38.97% 39/1822 |
-10.95% 1124/1255 |
40.94% 19/1330 |
12.12% 102/1466 |
-1.25% 1343/1822 |
| 2020 | - - |
- - |
- - |
12.94% 351/1164 |
45.38% 10/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证新能源汽车ETF联接C VS. 长安沪深300非周期A(740101) |